Table 2.
Demographic characteristics and transplant outcomes – drop2 patients* versus the remaining steady adherence patient group.
| Drop2* (n = 44) | Steady Adherence (n =151) | P-value | |
|---|---|---|---|
| Female | 43% | 42% | .925 |
| Age | 46 ± 14 | 48 ± 14 | .356 |
| Donor type: | .397 | ||
| DD | 50% | 42% | |
| LRD | 36% | 36% | |
| LURD | 14% | 22% | |
| TX number: | .482 | ||
| 1 | 80% | 83% | |
| 2 | 16% | 14% | |
| 3 | 5% | 1% | |
| 4 | 0 | 1% | |
| Kidney & Pancreas | 20% | 34% | .078 |
| Diabetes at TX | 34% | 50% | .057 |
| Nonwhite | 18% | 3% | .002 |
| Teenaged | 2% | 3% | .726 |
| Drug-dose**: | .144 | ||
| AZA | 9% | 9% | |
| RAPA | 16% | 14% | |
| MMF – 2 times daily | 55% | 69% | |
| MMF – 4 times daily | 20% | 9% | |
| Corticosteroids after discharge | 34% | 37% | .716 |
| Initial immunosuppression | .849 | ||
| CSA | 66% | 62% | |
| Tacrolimus | 32% | 35% | |
| Only MMF | 2% | 3% | |
| Early acute rejection (<90d) | 16% | 5% | .020 |
| Transplant outcomes | |||
| Acute rejection a,b | 6.4 ± 1.6 | 2.5 ± .5 | .034 |
| Loss begore death a | 3.7 ± 1.2 | 1.6 ± .4 | .017 |
| Death a | 3.7 ± 1.1 | 2.7 ± .5 | .327 |
Drop2 indicates subjects whose calculated percentage of adherent days declined by a total of 2 or more days during the second monitored mo. compared to the first mo.
Drug-dose is initial drug and dose regimen at the time of hospital discharge.
Values are percent, or mean ± standard deviation, or rate per 100 patient-years ± standard error.
P-value for comparison by chi-square test or t-test.
Rates per 100 patient-years ± standard error.
For acute rejection, rates include repeated occurrences of acute rejection while log-rank test compares product-limit curves to first rejection (see Figure 1A). Acute rejections during the first 90 days after transplant were omitted.